Sustainable fiber-based materials for fungal rapid tests
About the webinar
Invasive fungal infections are a substantial cause of morbidity and mortality in critically ill or immunocompromised patients. A rapid and accurate diagnosis of these infections is a crucial step to identify the appropriate treatment and support the recovery of the patient.
While diagnosis via blood culture and skin biopsy can be unreliable and may delay treatment, lateral flow immuno assay tests are a rapid, cost-effective and noninvasive diagnostic screening alternative.
During this webinar, co-hosted with Lateral Dx, we will present the development of a competitive lateral flow test using Ahlstrom’s sustainable pad materials for the specific detection of Rhizopus arrhizus, the principal global agent of Mucormycosis in humans.
Thanks to these materials, these tests are not only efficient and reliable but can offer a more sustainable alternative to our customers.
Meet the speakers
Frédéric Bébien, Product Development & TCS Manager, Ahlstrom
Frédéric Bébien holds a Master’s Degree in Chemical Engineering – Formulation Chemistry from the University of Lyon, France. He joined Ahlstrom in 2006 as R&D Scientist, working on surface treatment chemistries and technologies. He has focused on developing untreated and pre-treated fiber-based materials for Lateral Flow Immuno Assay applications since 2014. He has been appointed Product Development and TCS Manager for Ahlstrom Lab & Life Science Business in 2022.
Richard Campbell, Founder/Managing Director, Lateral Dx
A leading expert in the development of lateral flow diagnostic tests and associated technology with over 25 years IVD industry experience. Extensive experience in contract development of lateral flow tests in all market areas including Human clinical, toxicology, veterinary, defence, environmental, agriculture/aquaculture. Founder and Managing Director of Lateral Dx Ltd, who offer Contract Development, Consultancy and Manufacture of lateral flow tests.